

SCORE Search Results Details for Application 10520296 and Search Result 20080731_165444_us-10-520-296-4.oligo.rag.

[Score Home Page](#)
 [Retrieve Application List](#)
 [SCORE System Overview](#)
 [SCORE FAQ](#)
 [Comments / Suggestions](#)

This page gives you Search Results detail for the Application 10520296 and Search Result 20080731_165444_us-10-520-296-4.oligo.rag.

[Go Back to previous page](#)

GenCore version 6.2.1
Copyright (c) 1993 - 2008 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: July 31, 2008, 17:13:00 ; Search time 66 Seconds
(without alignments)
63.680 Million cell updates/sec

Title: US-10-520-296-4
Perfect score: 7
Sequence: 1 ASSTDWS 7

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 3405708 seqs, 601879884 residues

Word size : 1

Total number of hits satisfying chosen parameters: 3299416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database : A_Geneseq_200711:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000:*
4: geneseqp2001:*
5: geneseqp2002:*
6: geneseqp2003a:*
7: geneseqp2003b:*
8: geneseqp2004a:*
9: geneseqp2004b:*
10: geneseqp2005:*
11: geneseqp2006:*
12: geneseqp2007:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	7	100.0	7	8 ADG14605	Adg14605 MBP83-89-
2	6	85.7	115	5 ADK35926	Adk35926 Novel hum
3	6	85.7	480	7 ADE81195	Ade81195 Orf11, SE
4	6	85.7	547	4 AAE07054	Aae07054 Human gen

5	6	85.7	547	5	ABG65102	Abg65102 Human alb
6	6	85.7	547	6	ADA55049	Ada55049 Human pro
7	6	85.7	547	8	ADL78369	Adl78369 Albumin f
8	6	85.7	547	10	AEE04690	Aee04690 Cancer-as
9	6	85.7	547	10	AEE04692	Aee04692 Cancer-as
10	6	85.7	547	11	AEH08642	Aeh08642 Therapeut
11	6	85.7	547	12	AG151470	Ag151470 Human The
12	6	85.7	594	5	ABU60933	Abu60933 Lung spec
13	6	85.7	594	5	ABU60982	Abu60982 Lung spec
14	5	71.4	10	4	AAG94691	Aag94691 Human com
15	5	71.4	11	10	AEC09392	Aec09392 DNA helic
16	5	71.4	12	11	AEI90313	Aei90313 SARS coro
17	5	71.4	15	2	AAW62155	Aaw62155 Agrobacte
18	5	71.4	15	8	ADJ25836	Adj25836 Beta-gluc
19	5	71.4	15	10	ADZ48583	Adz48583 A. faecae
20	5	71.4	20	10	ADZ98110	Adz98110 Human ami
21	5	71.4	34	10	AEA28141	Aea28141 Sericin p
22	5	71.4	35	11	AEE36720	Aee36720 Human ser
23	5	71.4	39	10	AED81597	Aed81597 Neurofila
24	5	71.4	44	11	AES91312	Aes91312 S. agalac
25	5	71.4	49	4	ABG13455	Abg13455 Novel hum
26	5	71.4	53	8	AFP91643	Afp91643 Glycine m
27	5	71.4	53	9	AFQ73379	Afq73379 Glycine m
28	5	71.4	55	6	ABU36051	Abu36051 Protein e
29	5	71.4	55	7	ADC88674	Adc88674 Ribosomal
30	5	71.4	55	10	AEA79379	Aea79379 Novel M.
31	5	71.4	55	10	AEB03476	Aeb03476 Mycobacte
32	5	71.4	56	4	AAU67046	Aau67046 Propionib
33	5	71.4	56	4	AAU56963	Aau56963 Propionib
34	5	71.4	56	6	ABM53482	Abm53482 Propionib
35	5	71.4	56	6	ABM63565	Abm63565 Propionib
36	5	71.4	59	12	AFK94093	Afk94093 SH3 domai
37	5	71.4	59	12	AFK96536	Afk96536 Natural S
38	5	71.4	61	4	AAU58790	Aau58790 Propionib
39	5	71.4	61	6	ABM55309	Abm55309 Propionib
40	5	71.4	62	4	AAU43260	Aau43260 Propionib
41	5	71.4	62	6	ABM39779	Abm39779 Propionib
42	5	71.4	64	5	ADK35271	Adk35271 Novel hum
43	5	71.4	65	9	AFQ72038	Afq72038 Glycine m
44	5	71.4	67	4	AAU14969	Aau14969 Novel bon
45	5	71.4	67	4	AAU14929	Aau14929 Novel bon

ALIGNMENTS

RESULT 1

ADG14605

ID ADG14605 standard; peptide; 7 AA.

XX

AC ADG14605;

XX

DT 11-MAR-2004 (first entry)

XX

CE MBP83-89-reactive TCR CDR3 sequence, SEQ ID NO:4.

XX

KW T cell receptor; TCR; MBP; myelin basic protein; MBP83-89 epitope;
 KW complementarity determining region; CDR3; MBP83-89-reactive TCR CDR3;
 KW autoimmune disease; vaccine; rheumatoid arthritis; myasthenia gravis;
 KW systemic lupus erythematosus; autoimmune thyroiditis; Graves' disease;
 KW inflammatory bowel disease; autoimmune uveoretinitis; polymyositis;
 KW diabetes; multiple sclerosis; MS; antiarthritic; antirheumatic; muscular;
 KW neuroprotective; antiinflammatory; dermatological; immunosuppressive;
 KW antithyroid; gastrointestinal; antidiabetic; human.

XX

OS Homo sapiens.

XX

FN W02003104407-A2.

XX

PD 18-DEC-2003.

XX

PF 05-JUN-2003; 2003WO-US017873.

XX

PR 05-JUN-2002; 2002US-0386287P.

XX

PA (BAY) BAYLOR COLLEGE MEDICINE.

PA (OPEX-) OPEXA PHARM INC.
 XX
 PI Zhang JZ;
 XX
 DR WPI; 2004-062334/06.
 DR N-PSDB; ADG14602.
 XX
 FT New oligonucleotide encoding a peptide, useful for diagnosing, monitoring
 PT or treating autoimmune diseases e.g. rheumatoid arthritis, myasthenia
 PT gravis, multiple sclerosis, systemic lupus erythematosus, autoimmune
 PT thyroiditis.
 XX
 FS Claim 1; SEQ ID NO 4; 33pp; English.
 XX
 CC The invention relates to oligonucleotides of 15-30 nucleotides in length
 CC encoding a CDR3 (complementarity determining region) sequence from a T
 CC cell receptor (TCR) reactive against the 83-99 immunodominant epitope of
 CC MBP (myelin basic protein). The invention also relates to a primer pair
 CC comprising an MBP83-89-reactive TCR CDR3 oligonucleotide and a TCR V-beta
 CC to C-beta region oligonucleotide; a labelled MBP83-89-reactive TCR CDR3
 CC oligonucleotide probe; a method of detecting MBP83-99 T cells expressing
 CC an MBP83-89-reactive TCR CDR3 motif; a vaccine comprising an MBP83-89-
 CC reactive TCR CDR3 peptide; and methods of monitoring and treating an
 CC autoimmune disease. The invention further discloses an antibody against
 CC an MBP83-89-reactive TCR CDR3 peptide. The vaccine of the invention may
 CC be used to treat autoimmune diseases including rheumatoid arthritis,
 CC myasthenia gravis, systemic lupus erythematosus, autoimmune thyroiditis,
 CC Graves' disease, inflammatory bowel disease, autoimmune uveoretinitis,
 CC polymyositis, certain types of diabetes, and especially multiple
 CC sclerosis (MS). The present sequence is related to the invention.
 XX
 SQ Sequence 7 AA;

Query Match 100.0%; Score 7; DB 8; Length 7;
 Best Local Similarity 100.0%; Pred. No. 2.9e+06;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASSTDWS 7
 |||||
 Db 1 ASSTDWS 7

RESULT 2

ADK35926

ID ADK35926 standard; protein; 115 AA.

XX

AC ADK35926;

XX

DT 06-MAY-2004 (first entry)

XX

DE Novel human polypeptide SeqID8008.

XX

KW antiarthritic; antiparkinsonian; neuroprotective; nootropic;
 KW immunosuppressive; cytostatic; antipsoriatic; antiinflammatory;
 KW antibacterial; antiviral; antifungal; antiparasitic; gene therapy;
 KW arthritis; Parkinson's; Alzheimer's; autoimmune disease; cancer;
 KW psoriasis; inflammatory bowel disease; infection; bacteria; virus;
 KW fungus; parasite; human.

XX

OS Homo sapiens.

XX

FR Key Location/Qualifiers

FT Misc-difference 1..115

FT /label= OTHER

FT /note= "OTHER= All Xaa's in this sequence are unknown
 FT amino acids or the site of a stop codon within the DNA
 FT sequence"

XX

FN WO200216439-A2.

XX

PD 28-FEB-2002.

XX

PF 05-MAR-2001; 2001WO-US004941.

XX

PR 07-MAR-2000; 2000US-00519705.

XX

PR 19-MAY-2000; 2000US-00574454.

XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Tang YT, Liu C, Drmanac RT;
 XX
 DR WPI; 2002-280918/32.
 XX
 FT Isolated polynucleotide encoding bone marrow derived polypeptides useful
 PT for treating, e.g., Parkinson's, Alzheimer's, cancer, arthritis, Crohn's
 PT disease, and inflammatory bowel disease.
 XX
 PS Claim 20; SEQ ID NO 8008; 504pp; English.
 XX
 CC This invention relates to a novel isolated polynucleotide comprising a
 CC nucleotide sequence selected from one of 1680 sequences, a mature protein
 CC coding portion of them, an active domain of them and their complementary
 CC sequences. The invention may be useful for the production of compounds
 CC with an antiarthritic, antiparkinsonian, neuroprotective, nootropic,
 CC immunosuppressive, cytostatic, antipsoriatic, antiinflammatory,
 CC antibacterial, antiviral, antifungal or antiparasitic activity. In
 CC addition, the disclosed sequences may be useful for gene therapy. The
 CC polypeptides or their antibodies are useful for treating many diseases
 CC such as arthritis, Parkinson's, Alzheimer's, autoimmune diseases, cancer,
 CC psoriasis, inflammatory bowel disease and infections caused by bacteria,
 CC viruses, fungi or parasites. The present sequence is that of a human
 CC polypeptide of the invention.
 XX
 SQ Sequence 115 AA;

Query Match 85.7%; Score 6; DB 5; Length 115;
 Best Local Similarity 100.0%; Pred. No. 62;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASSTDW 6
 |||||
 Db 2 ASSTDW 7

RESULT 3

ADE81195
 ID ADE81195 standard; protein; 480 AA.
 XX
 AC ADE81195;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE Orf11, SEQ ID 23.
 XX
 KW ML-236B; HMG-CoA reducing enzyme; Orf11.
 XX
 OS Penicillium citrinum.
 XX
 FN JP2003116567-A.
 XX
 EP 22-APR-2003.
 XX
 PF 15-OCT-2001; 2001JP-00316578.
 XX
 PR 15-OCT-2001; 2001JP-00316578.
 XX
 PA (SANY) SANKYO CO LTD.
 XX
 DR WPI; 2003-817677/77.
 DR N-PSDB; ADE81194.
 XX
 FT Novel DNA associated with synthesis of ML-236B, useful for improving ML-
 PT 236B production in ML-236B producing microbe.
 XX
 PS Example 8; SEQ ID NO 23; 142pp; Japanese.
 XX
 CC The present invention relates to a DNA sequence (I, ADE81173), which is
 CC associated with ML-236B synthesis. (I) is useful for improving ML-236B
 CC production in a HMG-CoA reducing-enzyme-inhibitor ML-236B producing
 CC microbe. The present sequence was used to illustrate the invention.
 XX
 SQ Sequence 480 AA;

Query Match 85.7%; Score 6; DB 7; Length 480;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 2 SSTDWS 7
 Db 88 SSTDWS 93

RESULT 4

AAE07054

ID AAE07054 standard; protein; 547 AA.

XX

AC AAE07054;

XX

DT 15-JUN-2007 (revised)

DT 16-OCT-2001 (first entry)

XX

DE Human gene 4 encoded secreted protein HSYAB05, SEQ ID NO:71.

XX

KW Human secreted protein; proliferative disorder; cancer; tumour;

KW foetal abnormality; developmental abnormality; haematopoietic disorder;

KW immune system disorder; AIDS; autoimmune disease; rheumatoid arthritis;

KW inflammation; allergy; neurological disorder; Alzheimer's disease;

KW Parkinson's disease; cognitive disorder; schizophrenia; asthma;

KW skin disorder; psoriasis; sepsis; diabetes; atherosclerosis;

KW cardiovascular disorder; angiogenic disorder; kidney disorder;

KW gastrointestinal disorder; pregnancy-related disorder;

KW endocrine disorder; infection; wound healing; vulnerability; cell culture;

KW chemotaxis; food additive; gene therapy; binding partner identification;

KW BOND_PC; KIAA1754; KIAA1754 [Homo sapiens]; bA127L20.2; RP11-127L20.4;

KW hypothetical protein LOC85450;

KW hypothetical protein LOC85450 [Homo sapiens]; 2; DANGER; bA127L20;

KW KIAA1754, isoform CRA_a; KIAA1754, isoform CRA_a [Homo sapiens];

KW novel protein; novel protein [Homo sapiens]; unnamed protein product;

KW unnamed protein product [Homo sapiens].

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Peptide 1..15

FT /label= Signal_peptide

FT Protein 16..547

FT /label= Mature_human_secreted_protein

XX

FN W0200154708-A1.

XX

PD 02-AUG-2001.

XX

PF 17-JAN-2001; 2001WD-US001434.

XX

FR 31-JAN-2000; 2000US-0179065P.

FR 04-FEB-2000; 2000US-0180628P.

FR 18-AUG-2000; 2000US-0226279P.

FR 05-DEC-2000; 2000US-0251988P.

FR 05-JAN-2001; 2001US-0259678P.

XX

FA (HUMA-) HUMAN GENOME SCI INC.

XX

PI Rosen CA, Komatsoulis GA, Baker KF, Birse CE, Soppet DR;

PI Olsen HS, Moore FA, Wei F, Ebner R, Duan DR, Shi Y, Choi GH;

PI Fiscella M, NI J, Ruben SM, Barash SC;

XX

DR WPI; 2001-488743/53.

DR N-FSDB; AAD13348.

DR FC:NCBI; g129789287.

XX

PT New isolated nucleic acids and polypeptides, useful for diagnosing,

PT treating and/or preventing human diseases and disorders.

XX

PS Claim 11; Page 489-491; 558pp; English.

XX

CC AAD13345-AAD13401 represent cDNAs corresponding to 22 human secreted

CC protein genes, and AAE07051-AAE07105 represent the proteins they encode.

CC AAE07106-AAE07129 represent human secreted protein fragments or variants.

CC The genes and their secreted proteins are useful for preventing, treating
 CC or ameliorating medical conditions, e.g., by protein or gene therapy.
 CC Pathological conditions can be diagnosed by determining the amount of the
 CC new protein in a sample or by determining the presence of mutations in
 CC the new genes. Specific uses are described for each of the 22 genes,
 CC based on the tissues in which they are most highly expressed, and include
 CC developing products for the diagnosis or treatment of proliferative
 CC disorders, cancer, tumours, foetal and developmental abnormalities,
 CC haemopoietic disorders, diseases of the immune system, AIDS, autoimmune
 CC diseases (e.g., rheumatoid arthritis), inflammation, allergies,
 CC neurological disorders (e.g., Alzheimer's disease, Parkinson's disease),
 CC cognitive disorders, schizophrenia, asthma, skin disorders (e.g.,
 CC psoriasis), sepsis, diabetes, atherosclerosis, cardiovascular disorders,
 CC angio-genic disorders, kidney disorders, gastrointestinal disorders,
 CC pregnancy-related disorders, endocrine disorders, and infections. The
 CC proteins can also be used to aid wound healing and epithelial cell
 CC proliferation, to prevent skin aging due to sunburn, to maintain organs
 CC before transplantation, for supporting cell culture of primary tissues,
 CC to regenerate tissues, to identify their cognate ligands or binding
 CC partners, and in chemotaxis, and can be used as a food additive or
 CC preservative to modify storage properties. Antibodies specific for a
 CC protein of the invention can be used in alleviating symptoms associated
 CC with the disorders mentioned above, and in diagnostic immunoassays e.g.,
 CC radioimmunoassay or enzyme linked immunosorbent assay (ELISA). The
 CC present sequence represents a human secreted protein of the invention
 CC
 CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed
 CC information from BOND.
 XX
 SQ Sequence 547 AA;

Query Match 85.7%; Score 6; DB 4; Length 547;
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASSTDW 6
 |||||
 Db 375 ASSTDW 380

RESULT 5
 ABG65102
 ID ABG65102 standard; protein; 547 AA.
 XX
 AC ABG65102;
 XX
 DT 15-JUN-2007 (revised)
 DT 27-AUG-2002 (first entry)
 XX
 DE Human albumin fusion protein #1777.
 XX
 KW Albumin fusion protein; therapeutic protein X; human albumin; HA;
 KW human serum albumin; HSA; cancer; reproductive disorder;
 KW digestive disorder; immune disorder; endocrine disorder;
 KW haematopoietic disorder; neural disorder; connective disorder;
 KW cytostatic; antiinfertility; antiinflammatory; antiulcer;
 KW immunomodulator; anti-HIV; antidiabetic; haemostatic; nootropic;
 KW neuroprotective; antiparkinsonian; antimicrobial; neuroleptic;
 KW osteopathic; antiarthritic; BOND_PC; KIAA1754; KIAA1754 [Homo sapiens];
 KW bA127L20.2; RP11-127L20.4; hypothetical protein LOC85450;
 KW hypothetical protein LOC85450 [Homo sapiens]; 2; DANGER; bA127L20;
 KW KIAA1754, isoform CRA_a; KIAA1754, isoform CRA_a [Homo sapiens];
 KW novel protein; novel protein [Homo sapiens]; unnamed protein product;
 KW unnamed protein product [Homo sapiens].
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FN WO200177137-A1.
 XX
 PD 18-OCT-2001.
 XX
 PF 12-APR-2001; 2001WO-US011988.
 XX
 PR 12-APR-2000; 2000US-0229358P.
 PR 25-APR-2000; 2000US-0199384P.

PR 21-DEC-2000; 2000US-0256931P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Rosen CA, Haseltine WA;
 XX
 DR WPI; 2002-010886/01.
 DR FC:NCBI; g129789287.
 XX
 PT New fusion protein for treating disease e.g. diabetes comprises an
 PT albumin fused to a therapeutic protein.
 XX
 PS Claim 1; Page 1750-1752; 2102pp; English.
 XX
 CC The present invention relates to albumin fusion proteins comprising a
 CC therapeutic protein X and human albumin (HA, also known as human serum
 CC albumin, HSA). The proteins are useful for treating a disease or disorder
 CC that may be modulated by therapeutic protein X. The albumin extends the
 CC shelf-life of protein X, and may increase its biological in vitro/in vivo
 CC activity. The protein is useful for treating and diagnosing disorders
 CC such as cancer, reproductive disorders, digestive disorders (e.g. Crohn's
 CC disease, ulcerative colitis), immune disorders (e.g. acquired
 CC immunodeficiency syndrome, AIDS), endocrine disorders (e.g. diabetes),
 CC haematopoietic disorders, neural disorders (e.g. Alzheimer's,
 CC Parkinson's, Creutzfeldt-Jacob disease, encephalomyelitis, meningitis,
 CC schizophrenia), and connective disorders (e.g. osteoporosis, arthritis).
 CC ABG63326-ABG65518 represent albumin fusion proteins of the invention
 CC
 CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed
 CC information from BOND.
 XX
 SQ Sequence 547 AA;

Query Match 85.7%; Score 6; DB 5; Length 547;
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASSTDW 6
 |||||
 Db 375 ASSTDW 380

RESULT 6
 ADA55049

ID ADA55049 standard; protein; 547 AA.
 XX
 AC ADA55049;
 XX
 DT 15-JUN-2007 (revised)
 DT 20-NOV-2003 (first entry)
 XX
 DE Human protein, SEQ ID 2617.
 XX
 KW Cytostatic; Anti-inflammatory; Osteopathic; Neuroprotective; Nootropic;
 KW Gene therapy; human; secretory protein; membrane proteins; cancer;
 KW inflammatory disease; osteoporosis; neurological disease; BOND_PC;
 KW KIAA1754; KIAA1754 [Homo sapiens]; bA127L20.2; RP11-127L20.4;
 KW hypothetical protein LOC85450;
 KW hypothetical protein LOC85450 [Homo sapiens]; 2; DANGER; bA127L20;
 KW KIAA1754, isoform CRA_a; KIAA1754, isoform CRA_a [Homo sapiens];
 KW novel protein; novel protein [Homo sapiens]; unnamed protein product;
 KW unnamed protein product [Homo sapiens].
 XX
 OS Homo sapiens.
 XX
 FN EP1293569-A2.
 XX
 FD 19-MAR-2003.
 XX
 FE 21-MAR-2002; 2002EP-00006586.
 XX
 PR 14-SEP-2001; 2001JP-00328381.
 PR 24-JAN-2002; 2002US-0350435P.
 XX
 PA (HELI-) HELIX RES INST.
 PA (REAS-) RES ASSOC BIOTECHNOLOGY.

XX
 PI Isoqai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;
 PI Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Irie R, Tamechika I;
 PI Seki N, Yoshikawa T, Otsuka M, Nagahari K, Masuho Y;
 XX
 DR WPI; 2003-395539/38.
 DR N-PSDB; ADA53410.
 DR PC:NCBI; gi29789287.
 XX
 PT New polynucleotides encoding full-length polypeptides, e.g. secretory
 PT and/or membrane proteins, useful for developing medicines for diseases in
 PT which the gene is involved, or as target molecules for gene therapy.
 XX
 FS Claim 14; SEQ ID NO 2617; 205pp; English.
 XX
 CC The present invention relates to novel human secretory or membrane
 CC proteins (ADA54072-ADA55710) and their coding sequences (ADA52433-
 CC ADA54071). The coding sequences are useful in the gene therapy of
 CC diseases caused by abnormalities of the proteins, e.g. cancer,
 CC inflammatory diseases, osteoporosis or neurological disease.
 CC
 CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed
 CC information from BOND.
 XX
 SQ Sequence 547 AA;

Query Match 85.7%; Score 6; DB 6; Length 547;
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASSTDW 6
 Db 375 ASSTDW 380

RESULT 7

ADL78369

ID ADL78369 standard; protein; 547 AA.

XX

AC ADL78369;

XX

DT 20-MAY-2004 (first entry)

XX

DE Albumin fusion protein related therapeutic protein X, SEQ ID No 1851.

XX

KW albumin fusion protein; cytostatic; antianaemic; antiarthritic;

KW antiasthmatic; anti-HIV; immunosuppressive; antiinflammatory;

KW antipsoriatic; antibacterial; osteopathic; dermatological; antigout;

KW immunomodulator; antiarrhythmic; cardiant; nootropic; antilipaemic;

KW nephrotropic; uropathic; neuroprotective; antiparkinsonian; tranquilizer;

KW antidiabetic; anabolic; hypertensive; vulnerary; gene therapy; cancer;

KW reproductive system disorder; therapeutic protein.

XX

CS Unidentified.

XX

FN US2004010134-A1.

XX

PD 15-JAN-2004.

XX

PF 12-APR-2001; 2001US-00833245.

XX

PR 12-APR-2000; 2000US-0229358P.

PR 25-APR-2000; 2000US-0199384P.

PR 21-DEC-2000; 2000US-0256931P.

XX

FA (ROSE/) ROSEN C A.

FA (HASE/) HASELTINE W A.

XX

PI Rosen CA, Haseltine WA;

XX

DR WPI; 2004-090519/09.

XX

PT New albumin fusion proteins, useful for diagnosing, treating, preventing

PT or ameliorating diseases or disorders e.g. cancer, anemia, arthritis,

PT asthma, inflammatory bowel disease or Alzheimer's disease.

XX

PS Disclosure; SEQ ID NO 1851; 279pp; English.

XX

CC The invention relates to a novel albumin fusion protein. The invention

CC further relates to: a composition comprising the albumin fusion protein

CC and a pharmaceutical carrier; a kit comprising the composition of the

CC albumin fusion protein formula; a method of treating a disease or

CC disorder in a patient comprising the step of administering the albumin

CC fusion protein; a method of treating a patient with a disease or disorder

CC that is modulated by Therapeutic protein; X, or its fragment or variant;

CC a method of extending the shelf life of Therapeutic protein; X, or its

CC fragment or variant; a nucleic acid molecule comprising a polynucleotide

CC sequence encoding the albumin fusion protein; a vector comprising the

CC nucleic acid molecule of the albumin fusion protein; and a host cell

CC comprising the nucleic acid molecule of the albumin fusion protein. The

CC albumin fusion protein and its compositions have the following

CC activities: cytostatic, antianemic, antiarthritic, antiasthmatic, anti-

CC HIV, immunosuppressive, antiinflammatory, antipsoriatic, antibacterial,

CC osteopathic, dermatological, antigout, immunomodulator, antiarrhythmic,

CC cardiant, nootropic, antilipemic, nephrotropic, uropathic,

CC neuroprotective, antiparkinsonian, tranquilizer, antidiabetic, anabolic,

CC hypertensive, and vulnerary. The albumin fusion protein nucleic acid may

CC be used in gene therapy to treat disorders. The albumin fusion protein is

CC useful for diagnosing, treating, preventing or ameliorating diseases or

CC disorders comprising indication: Y. The diseases or disorders include:

CC cancer (e.g. leukaemia, colon, bone, breast, liver or lung cancer),

CC immune or haematopoietic diseases (e.g. anaemia, Hodgkin's disease, acute

CC lymphocytic anaemia, multiple myeloma, arthritis, asthma, AIDS,

CC autoimmune disease, inflammatory bowel disease, psoriasis or Lyme

CC disease), reproductive system disorders (e.g. prostatitis, inguinal

CC hernia, varicocele, penile carcinoma, ovarian adenocarcinoma or Sertoli-

CC Leydig tumours), musculoskeletal diseases (e.g. giant cell tumours,

CC Paget's disease, systemic lupus erythematosus, gout, muscular dystrophy

CC or cachexia), cardiovascular disease (e.g. rhabdomyomas, heart disease,

CC arrhythmia, cardiac arrest, heat valve disease, hypernatraemia or

CC hyponatraemia), mixed foetal diseases (e.g. foetal alcohol syndrome,

CC Down's syndrome, Patau syndrome, Turner's syndrome, Apert syndrome or Tay

CC -Sachs disease), excretory diseases (e.g. urinary incontinence, urinary

CC tract infections or renal disorders), neural or sensory disease (e.g.

CC Alzheimer's disease, Parkinson's disease, cerebral malaria, meningitis,

CC cerebellar ataxia, attention deficit disorder, autism or obsessive

CC compulsive disorder), respiratory disease (e.g. emphysema, lung cancer or

CC occupational lung disease), endocrine diseases (e.g. diabetes, Addison's

CC disease or glomerulonephritis), digestive diseases (e.g. portal

CC hypertension, irritable bowel disease, gastric atrophy or pancreatitis)

CC or connective tissue or epithelial diseases (e.g. Crohn's disease,

CC scleroderma, wound healing or epidermolysis bullosa). This sequence

CC represents a therapeutic protein X relating to the albumin fusion protein

CC of the invention. The sequence listing data for this specification was

CC downloaded from the USPTO website.

XX

SG Sequence 547 AA;

Query Match 85.7%; Score 6; DB 8; Length 547;
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASSTDW 6
 |||||
 Db 375 ASSTDW 380

RESULT 8

AEE04690

ID AEE04690 standard; protein; 547 AA.

XX

AC AEE04690;

XX

DT 15-JUN-2007 (revised)

DT 26-JAN-2006 (first entry)

XX

DE Cancer-associated protein SEQ ID NO:8.

XX

KW cancer; microarray; hybridoma; monoclonal antibody; screening;

KW RNA interference; diagnosis; cytostatic; neoplasm; BOND_PC; KIAA1754;

KW KIAA1754 [Homo sapiens]; ba127L20.2; RP11-127L20.4;

KW hypothetical protein LOC85450;

KW hypothetical protein LOC85450 [Homo sapiens]; 2; DANGER; ba127L20;
KW KIAA1754, isoform CRA_a; KIAA1754, isoform CRA_a [Homo sapiens];
KW novel protein; novel protein [Homo sapiens]; unnamed protein product;
KW unnamed protein product [Homo sapiens].
XX
OS Homo sapiens.
XX
FN WO2005107396-A2.
XX
PD 17-NOV-2005.
XX
PF 02-MAY-2005; 2005WO-US014965.
XX
FR 30-APR-2004; 2004US-00836956.
XX
FA (CHIR) CHIRON CORP.
XX
FI Morris DW, Malandro MS, Lai A, Tse C, Fattaey A;
XX
WI WPI; 2005-769640/78.
DR N-PSDB; AEE04689.
DR PC:NCBI; g129789287.
XX
PT New cancer-associated (CA) polynucleotide comprising at least 10
PT contiguous nucleotides, useful in preparing a composition for diagnosing
PT or treating cancer.
XX
PF Claim 18; SEQ ID NO 8; 148pp; English.
XX
CC The invention relates to new isolated cancer-associated nucleic acid and
CC polypeptide sequences. Also included are the following: a host cell
CC comprising the recombinant nucleic acid or expression vector; an
CC expression vector comprising the isolated nucleic acid; a microarray for
CC detecting a cancer associated (CA) nucleic acid comprising at least one
CC probe comprising at least 10 contiguous nucleotides of the sequence given
CC in the specification; an isolated polypeptide encoded within an open
CC reading frame of a CA sequence; an isolated antibody or its antigen
CC binding fragment that binds to the polypeptide; a hybridoma that produces
CC the monoclonal antibody; a kit for detecting cancer cells comprising the
CC antibody; a kit for diagnosing the presence of cancer in a test sample,
CC comprising at least one polynucleotide that selectively hybridizes to a
CC CA polynucleotide sequence; a method for detecting a presence or an
CC absence of cancer cells in an individual; an electronic library
CC comprising the polynucleotide or polypeptide or its fragment comprising
CC the CA polynucleotide or polypeptide sequence, or its complement; a
CC method of screening for anticancer activity; a method for detecting
CC cancer associated with expression of a polypeptide in a test cell sample;
CC a method for screening for a bioactive agent capable of modulating the
CC activity of a CA protein (CAP), where the CAP is encoded by the nucleic
CC acid sequence given in the specification; a method for diagnosing cancer;
CC a method for treating cancer; and a method for inhibiting expression of a
CC cancer associated (CA) gene in a cell. Inhibiting expression of a cancer
CC associated (CA) gene in a cell comprises contacting a cell expressing a
CC CA gene with a double stranded RNA comprising a sequence capable of
CC hybridizing to a cancer associated (CA) mRNA corresponding to the
CC polynucleotide sequences given in the specification, in an amount
CC sufficient to elicit RNA interference and inhibiting expression of the CA
CC gene in the cell. The double stranded RNA is provided by introducing a
CC short interfering RNA (siRNA) into the cell by transfection,
CC electroporation or microinjection. The double stranded RNA is provided by
CC introducing a short interfering RNA (siRNA) into the cell by an
CC expression vector. The polynucleotides are useful in preparing a
CC composition for diagnosing or treating cancer. The present sequence
CC represents a cancer-associated protein of the invention. Note: This
CC sequence is not shown in the specification but was obtained in electronic
CC format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences/17.11.2005/.
CC
CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed
CC information from BOND.
XX
SQ Sequence 547 AA;

Query Match 85.7%; Score 6; DB 10; Length 547;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASSTDW 6
 Db 375 ASSTDW 380

RESULT 9

AEE04692

ID AEE04692 standard; protein; 547 AA.

XX

AC AEE04692;

XX

DT 15-JUN-2007 (revised)

DT 26-JAN-2006 (first entry)

XX

DE Cancer-associated protein SEQ ID NO:10.

XX

KW cancer; microarray; hybridoma; monoclonal antibody; screening;

KW RNA interference; diagnosis; cytostatic; neoplasm; BOND_PC; KIAA1754;

KW KIAA1754 [Homo sapiens]; ba127L20.2; RP11-127L20.4;

KW hypothetical protein LOC85450;

KW hypothetical protein LOC85450 [Homo sapiens]; 2; DANGER; ba127L20;

KW KIAA1754, isoform CRA_a; KIAA1754, isoform CRA_a [Homo sapiens];

KW novel protein; novel protein [Homo sapiens]; unnamed protein product;

KW unnamed protein product [Homo sapiens].

XX

OS Homo sapiens.

XX

FN WO2005107396-A2.

XX

FD 17-NOV-2005.

XX

FE 02-MAY-2005; 2005WO-US014965.

XX

FR 30-APR-2004; 2004US-00836956.

XX

FA (CHIR) CHIRON CORP.

XX

PI Morris DW, Malandro MS, Lai A, Tse C, Fattaey A;

XX

DR WPI; 2005-769640/78.

DR N-PSDB; AEE04691.

DR PC:NCBI; gi29789287.

XX

PT New cancer-associated (CA) polynucleotide comprising at least 10

PT contiguous nucleotides, useful in preparing a composition for diagnosing

PT or treating cancer.

XX

PS Claim 18; SEQ ID NO 10; 148pp; English.

XX

CC The invention relates to new isolated cancer-associated nucleic acid and

CC polypeptide sequences. Also included are the following: a host cell

CC comprising the recombinant nucleic acid or expression vector; an

CC expression vector comprising the isolated nucleic acid; a microarray for

CC detecting a cancer associated (CA) nucleic acid comprising at least one

CC probe comprising at least 10 contiguous nucleotides of the sequence given

CC in the specification; an isolated polypeptide encoded within an open

CC reading frame of a CA sequence; an isolated antibody or its antigen

CC binding fragment that binds to the polypeptide; a hybridoma that produces

CC the monoclonal antibody; a kit for detecting cancer cells comprising the

CC antibody; a kit for diagnosing the presence of cancer in a test sample,

CC comprising at least one polynucleotide that selectively hybridizes to a

CC CA polynucleotide sequence; a method for detecting a presence or an

CC absence of cancer cells in an individual; an electronic library

CC comprising the polynucleotide or polypeptide or its fragment comprising

CC the CA polynucleotide or polypeptide sequence, or its complement; a

CC method of screening for anticancer activity; a method for detecting

CC cancer associated with expression of a polypeptide in a test cell sample;

CC a method for screening for a bioactive agent capable of modulating the

CC activity of a CA protein (CAP), where the CAP is encoded by the nucleic

CC acid sequence given in the specification; a method for diagnosing cancer;

CC a method for treating cancer; and a method for inhibiting expression of a

CC cancer associated (CA) gene in a cell. Inhibiting expression of a cancer

CC associated (CA) gene in a cell comprises contacting a cell expressing a

CC CA gene with a double stranded RNA comprising a sequence capable of

CC hybridizing to a cancer associated (CA) mRNA corresponding to the

CC polynucleotide sequences given in the specification, in an amount
 CC sufficient to elicit RNA interference and inhibiting expression of the CA
 CC gene in the cell. The double stranded RNA is provided by introducing a
 CC short interfering RNA (siRNA) into the cell by transfection,
 CC electroporation or microinjection. The double stranded RNA is provided by
 CC introducing a short interfering RNA (siRNA) into the cell by an
 CC expression vector. The polynucleotides are useful in preparing a
 CC composition for diagnosing or treating cancer. The present sequence
 CC represents a cancer-associated protein of the invention. Note: This
 CC sequence is not shown in the specification but was obtained in electronic
 CC format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences/17.11.2005/.
 CC
 CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed
 CC information from BOND.
 XQ
 SQ Sequence 547 AA;

Query Match 85.7%; Score 6; DB 10; Length 547;
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Gy 1 ASSTDW 6
 |||||
 Db 375 ASSTDW 380

RESULT 10

AEH08642
 ID AEH08642 standard; protein; 547 AA.
 XX
 AC AEH08642;
 XX
 DT 15-JUN-2007 (revised)
 DT 15-JUN-2006 (first entry)
 XX
 DE Therapeutic protein HSYAB05, SEQ ID 1851.
 XX
 KW protein therapy; gene therapy; cancer; cytostatic; BOND_PC; KIAA1754;
 KW KIAA1754 [Homo sapiens]; ba127L20.2; RP11-127L20.4;
 KW hypothetical protein LOC85450;
 KW hypothetical protein LOC85450 [Homo sapiens]; 2; DANGER; ba127L20;
 KW KIAA1754, isoform CRA_a; KIAA1754, isoform CRA_a [Homo sapiens];
 KW novel protein; novel protein [Homo sapiens]; unnamed protein product;
 KW unnamed protein product [Homo sapiens].
 XX
 OS Homo sapiens.
 XX
 FN US2006084794-A1.
 XX
 PD 20-APR-2006.
 XX
 FF 02-NOV-2005; 2005US-00264096.
 XX
 FR 12-APR-2001; 2001US-00833245.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Rosen CA, Haseltine WA;
 XX
 DR WPI; 2006-299363/31.
 DR PC:NCBI; gi29789287.
 XX
 PT New albumin fusion protein comprises Therapeutic protein X and albumin,
 PT or its fragments or variants, useful for treating, preventing, or
 PT ameliorating, e.g. neural disorders, muscular disorders, renal disorders,
 PT or cancerous diseases.
 XX
 PS Disclosure; SEQ ID NO 1851; 257pp; English.
 XX
 CC The present invention relates to albumin fusion proteins comprising a
 CC Therapeutic protein X and albumin (AEH06831). The albumin fusion proteins
 CC are useful for treating, preventing, or ameliorating diseases or
 CC disorders that are modulated by Therapeutic protein X by protein or gene
 CC therapy. Diseases include neural disorders, immune system disorders,
 CC muscular disorders, reproductive disorders, gastrointestinal disorders,

CC pulmonary disorders, cardiovascular disorders, renal disorders,
 CC proliferative disorders, and/or cancerous diseases. The present sequence
 CC is one such therapeutic protein.
 CC
 CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed
 CC information from BOND.
 XX
 SQ Sequence 547 AA;

Query Match 85.7%; Score 6; DB 11; Length 547;
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Gy 1 ASSTDW 6
 Db 375 ASSTDW 380

RESULT 11
 AGI51470
 ID AGI51470 standard; protein; 547 AA.
 XX
 AC AGI51470;
 XX
 DT 04-OCT-2007 (first entry)
 XX
 DE Human Therapeutic protein X amino acid sequence SEQ ID NO:1851.
 XX
 KW albumin; fusion protein; therapeutic; pharmaceutical; vulnerary;
 KW vasotropic; respiratory-gen.; osteopathic; neuroprotective; nephrotropic;
 KW muscular-gen.; immunomodulator; gastrointestinal-gen.; endocrine-gen.;
 KW cytotatic; cardiovascular-gen.; antimicrobial; gene therapy;
 KW wound healing; respiratory disease; reproduction disorder; renal disease;
 KW neurological disease; neoplasm; neoplasia; musculoskeletal disease;
 KW infectious disease; immune disorder; hemopoiesis;
 KW gastrointestinal function disorder; gastrointestinal disease;
 KW endocrine disease; cardiovascular disease; therapeutic protein X;
 KW BOND_PC; KIAA1754; ba127L20.2; RP11-127L20.4;
 KW hypothetical protein LOC85450; 2; DANGER; ba127L20;
 KW KIAA1754, isoform CRA_a; novel protein; unnamed protein product.
 XX
 OS Homo sapiens.
 XX
 FX US2007099833-A1.
 XX
 PD 03-MAY-2007.
 XX
 PF 11-OCT-2006; 2006US-00545766.
 XX
 PR 12-APR-2001; 2001US-00833245.
 PR 02-NOV-2005; 2005US-00264096.
 XX
 FA (HUMA-) HUMAN GENOME SCI INC.
 XX
 FI Rosen CA, Haseltine WA;
 XX
 DR WPI; 2007-494526/48.
 DR PC:NCBI; g129789287.
 XX
 PT New albumin fusion protein, useful for treating, preventing, or
 PT ameliorating diseases, e.g. neoplastic, hematopoietic, reproductive,
 PT cardiovascular, renal, neurological, respiratory, digestive, endocrine,
 PT wound, or infectious diseases.
 XX
 FS Disclosure; SEQ ID NO 1851; 259pp; English.
 XX
 CC The invention relates to an albumin fusion protein comprising a
 CC Therapeutic protein X and albumin. Also described: (1) a composition
 CC comprising the albumin fusion protein and a pharmaceutical carrier; (2) a
 CC kit comprising the composition; (3) a method of treating a disease or
 CC disorder in a patient; (4) a method of extending the shelf life of
 CC Therapeutic protein X or a fragment of variant of a Therapeutic X; (5) a
 CC method of prolonging the serum half-life of Therapeutic protein X or a
 CC fragment of variant of a Therapeutic X; (6) a nucleic acid molecule
 CC comprising a polynucleotide sequence encoding the albumin fusion protein;
 CC (7) a vector comprising the nucleic acid molecule of (6); and (8) a host

cell comprising the nucleic acid molecule of (6). The albumin fusion proteins, nucleic acid molecules, compositions, and methods are useful for treating, preventing, or ameliorating diseases, disorders or conditions, e.g. neoplastic, immune, hematopoietic, reproductive, musculoskeletal, cardiovascular, renal, neurological, respiratory, digestive, endocrine, wound, or infectious diseases, disorders or conditions. The present invention provides stabilized, long lasting formulations of proteinaceous therapeutic molecules that are easily dispensed, preferably with a simple formulation requiring minimal post-storage manipulation. The present sequence represents a human therapeutic protein X amino acid sequence, which is used in the exemplification of the present invention.

Revised record issued on 17-SEP-2007 : Enhanced with precomputed information from BOND.

Sequence 547 AA;

Query Match 85.7%; Score 6; DB 12; Length 547;
Best Local Similarity 100.0%; Prod.No. 2.5e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 ASSTDW 6
|||||
Db 375 ASSTDW 380

RESULT 12

ABU60933

ID ABU60933 standard; protein; 594 AA.

XX

AC ABU60933;

XX

DT 15-JUN-2007 (revised)

DT 08-MAY-2003 (first entry)

XX

DE Lung specific protein (LSP) #36.

XX

KW Human; gene therapy; vaccine; lung specific antigen; cancer diagnosis;

KW cancer monitoring; cancer staging; cancer imaging; lung cancer;

KW non-cancerous diseases of the lung; transgenic animal; BOND_PC;

KW KIAA1754 protein; KIAA1754 protein [Homo sapiens]; GO1747; GO3824;

KW G05488; G07399.

XX

OS Homo sapiens.

XX

PN WC200268633-A2.

XX

PD 06-SEP-2002.

XX

PF 21-NOV-2001; 2001WD-US043612.

XX

FR 22-NOV-2000; 2000US-0252500P.

XX

FA (DIAD-) DIADEXUS INC.

XX

PI Macina RA, Recipon H, Chen S, Sun Y, Liu C;

XX

DR WPI; 2002-713376/77.

DR PC:NCBI; gi12698053.

XX

PT New isolated human nucleic acid molecule and polypeptide, useful for

PT identifying, diagnosing, monitoring, staging, imaging and treating lung

PT cancer and non-cancerous diseases of the lung.

XX

FE Claim 11; Page 330-332; 389pp; English.

XX

CC The invention describes an isolated human nucleic acid (I) encoding any

CC of 120 10-1533 residue amino acid sequences (S1), given in the

CC specification, comprising any of 164 179-12421 base pair sequences (S2),

CC given in the specification. The methods and compositions of the present

CC invention are useful for identifying, diagnosing, monitoring, staging,

CC imaging and treating lung cancer and non-cancerous diseases of the lung.

CC They are also used for identifying lung tissue, monitoring and

CC identifying and/or designing antagonists of the polypeptide of the

CC invention, gene therapy, production of transgenic animals and production

CC of engineered lung tissue for treatment and research. This is the amino
 CC acid sequence of a lung specific nucleic acid
 CC
 CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed
 CC information from BOND.
 XX
 SQ Sequence 594 AA;

Query Match 85.7%; Score 6; DB 5; Length 594;
 Best Local Similarity 100.0%; Pred. No. 2.7e+02;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ASSTDW 6
 |||||
 Db 422 ASSTDW 427

RESULT 13

ABU60982
 ID ABU60982 standard; protein; 594 AA.
 XX
 AC ABU60982;
 XX
 DT 15-JUN-2007 (revised)
 DT 08-MAY-2003 (first entry)
 XX
 DE Lung specific protein (LSP) #85.
 XX
 KW Human; gene therapy; vaccine; lung specific antigen; cancer diagnosis;
 KW cancer monitoring; cancer staging; cancer imaging; lung cancer;
 KW non-cancerous diseases of the lung; transgenic animal; BOND_FC;
 KW KIAA1754 protein; KIAA1754 protein [Homo sapiens]; G01747; G03824;
 KW G05488; G07399.
 XX
 OS Homo sapiens.
 XX
 FN W0200268633-A2.
 XX
 PD 06-SEP-2002.
 XX
 PF 21-NOV-2001; 2001WD-US043612.
 XX
 FR 22-NOV-2000; 2000US-0252500P.
 XX
 PA (DIAD-) DIADEXUS INC.
 XX
 PI Macina RA, Recipon H, Chen S, Sun Y, Liu C;
 XX
 DR WPI; 2002-713376/77.
 DR PC:NCBI; gi12698053.
 XX
 PT New isolated human nucleic acid molecule and polypeptide, useful for
 PT identifying, diagnosing, monitoring, staging, imaging and treating lung
 PT cancer and non-cancerous diseases of the lung.
 XX
 PS Claim 11; Page 365-367; 389pp; English.
 XX
 CC The invention describes an isolated human nucleic acid (I) encoding any
 CC of 120 10-1533 residue amino acid sequences (S1), given in the
 CC specification, comprising any of 164 179-12421 base pair sequences (S2),
 CC given in the specification. The methods and compositions of the present
 CC invention are useful for identifying, diagnosing, monitoring, staging,
 CC imaging and treating lung cancer and non-cancerous diseases of the lung.
 CC They are also used for identifying lung tissue, monitoring and
 CC identifying and/or designing antagonists of the polypeptide of the
 CC invention, gene therapy, production of transgenic animals and production
 CC of engineered lung tissue for treatment and research. This is the amino
 CC acid sequence of a lung specific nucleic acid
 CC
 CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed
 CC information from BOND.
 XX
 SQ Sequence 594 AA;

Query Match 85.7%; Score 6; DB 5; Length 594;
 Best Local Similarity 100.0%; Pred. No. 2.7e+02;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASSTDW 6
 |||||
 Db 422 ASSTDW 427

RESULT 14

AAG94691
 ID AAG94691 standard; peptide; 10 AA.
 XX
 AC AAG94691;
 XX
 DT 18-SEP-2001 (first entry)
 XX
 DE Human complementary peptide, SEQ ID NO: 885.
 XX
 KW Human; complementary peptide; ligand; drug discovery; drug design.
 XX
 OS Homo sapiens.
 XX
 FN WO200142277-A2.
 XX
 PD 14-JUN-2001.
 XX
 PF 13-DEC-2000; 2000WO-GB004776.
 XX
 PR 13-DEC-1999; 99GB-00029464.
 XX
 FA (PROT-) PROTEOM LTD.
 XX
 FI Roberts GW, Heal JR;
 XX
 DR WPI; 2001-408419/43.
 XX
 PT A set of peptide ligands consisting of specific complementary peptides to
 PT proteins encoded by genes of the human genome, useful in an assay for
 PT screening and identifying of one or more novel peptides which are drug
 PT candidates or pro-drugs.
 XX
 PS Example 4; Page 166; 646pp; English.
 XX
 CC The invention relates to a set of complementary peptide ligands generated
 CC from the human genome. The complementary peptides interact with their
 CC relevant target proteins encoded in the human genome. They can be used as
 CC reagents in drug discovery and as lead ligands to facilitate drug design
 CC and development. The present sequence is a complementary peptide provided
 CC in the specification
 XX
 SQ Sequence 10 AA;

Query Match 71.4%; Score 5; DB 4; Length 10;
 Best Local Similarity 100.0%; Pred. No. 83;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASSTD 5
 |||||
 Db 5 ASSTD 9

RESULT 15

AEC09392
 ID AEC09392 standard; peptide; 11 AA.
 XX
 AC AEC09392;
 XX
 DT 03-NOV-2005 (first entry)
 XX
 DE DNA helicase HEL308 peptide.
 XX
 KW antibody identification; multiple sclerosis; neuroprotective;
 KW immune disorder; autoimmune disease; immunosuppressive;
 KW neurological disease; psychiatric disorder; DNA helicase; HEL308.
 XX
 OS Synthetic.
 XX

PN WO2005080985-A2.
 XX
 PD 01-SEP-2005.
 XX
 FE 18-FEB-2005; 2005WO-US005146.
 XX
 FR 18-FEB-2004; 2004US-0545980P.
 FR 18-FEB-2004; 2004US-0546062P.
 XX
 PA (RNTB-) ENTERON LP.
 XX
 PI Calenoff E;
 XX
 DR WPI; 2005-630435/64.
 XX
 FT Detecting disease caused by antibodies that complex with self-molecules
 FT in the subject, by identifying antigen molecule on a self molecule of the
 FT subject and detecting specific immunoglobulin antibody in biological
 FT fluid of subject.
 XX
 FS Disclosure; Fig 2; 54pp; English.
 XX
 CC The invention describes a method of detecting a disease in a subject
 CC caused or affected by antibodies that complex with self-molecules in the
 CC subject comprises identifying antigen molecule on a self molecule of the
 CC subject comprising one or more epitopes, and detecting specific
 CC immunoglobulin antibody in a biological fluid of the subject, where the
 CC antibody forms an immunocomplex with the epitopes on the antigen
 CC molecule, where the disease is detected. The method is useful for
 CC detecting an autoimmune disease (multiple sclerosis), a neurological
 CC disease, or a psychiatric disease in a subject caused or affected by
 CC antibodies that complex with self-molecules in the subject. This is the
 CC amino acid sequence of a DNA helicase HEL308 peptide that can be used as
 CC an epitope for treatment of multiple sclerosis.
 XX
 SQ Sequence 11 AA;

Query Match 71.4%; Score 5; DB 10; Length 11;
 Best Local Similarity 100.0%; Pred. No. 91;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ASSTD 5
 |||||
 Db 5 ASSTD 9

Search completed: July 31, 2008, 17:17:58
 Job time : 67.4113 secs

SCORE 3.9